Ergogenic effects of a 10-day L-citrulline supplementation on time to exhaustion and cardiorespiratory and metabolic responses in healthy individuals: a double-blind, randomised, placebo-controlled crossover trial.
10日間のL-シトルリン補給が健康な個人の疲労困憊までの時間と心肺・代謝応答に及ぼすエルゴジェニック効果:二重盲検ランダム化プラセボ対照クロスオーバー試験 (機械翻訳の邦題)
記録の確認項目
- 研究デザイン
- その他の原著論文
- 対象
- 未確定
- 出版年
- 2025
- 出典
- doi.org
- 抄録の表示
- 表示あり
- 出版状態
- 有効な記録
- 状態確認日
- 2026/08/17
- 収集日
- 2026/08/03
- 鮮度
- 確認期限内
- 確認段階
- 自動処理
- 記録状態
- 公開
日本語要約(機械生成)
本研究は、健康な若年成人を対象に、10日間のL-シトルリン補給(100 mg/kg/日)が疲労困憊までの時間(TTE)および心肺・代謝応答に及ぼす影響を検討した二重盲検ランダム化プラセボ対照クロスオーバー試験である。20名の被験者(女性9名)が、L-シトルリンまたはプラセボを10日間摂取し、第2乳酸閾値の5%上でTTEテストを実施した。その結果、TTEは両群間で有意差はなかった(CIT 20.5±7.3分 vs PLA 19.8±5.7分、p=0.43)。女性サブグループでは傾向がみられた(24.4±6.2分 vs 21.9±4.8分、p=0.06)。心拍出量、酸素摂取量、血圧にも有意差はなかった。結論として、10日間のL-シトルリン補給は健康な中程度活動的な個人の持久性パフォーマンスを向上させない。
この要約は公開抄録のみを根拠にAIが機械的に生成したものです。正確な内容は原文を確認してください。
抄録
Introduction: L-Citrulline supplementation has been a topic of debate due to its potential to augment L-arginine bioavailability and nitric oxide production. However, it remains uncertain whether it can truly serve as an ergogenic aid in endurance exercise performance. While it was previously recommended to include higher continuous doses of L-citrulline over ≥7 days, this study aimed to investigate whether a relative dosing strategy using 100 mg·kg-1 per day over 10 days could improve time to exhaustion (TTE) in healthy young adults.Methods: Twenty healthy, moderately active adult participants (nine females; age, 24.4 ± 0.9 years; BMI, 24.0 ± 2.5 kg·m-2; V̇O2max, 43.5 ± 6.3 mL·min-1·kg-1) received either 100 mg·kg-1 per day of L-citrulline (CIT) or a placebo (PLA) for 10 days in a double-blind, randomised, placebo-controlled crossover trial, before they performed two TTE tests at 5% above the second lactate turnpoint (LTP2). Cardiac output (Q̇), oxygen uptake (V̇O2), blood glucose ([Glu-]) and lactate concentrations ([La-]), and rating of perceived exertion (RPE) were quantified during each test.Results: There was no statistically significant difference in TTE between the trial arms (CIT vs. PLA: 20.5 ± 7.3 vs. 19.8 ± 5.7 min, p = 0.43). However, a trend was observed in the female subgroup (24.4 ± 6.2 vs. 21.9 ± 4.8 min, p = 0.06). Cardiac output (Q̇) also did not show significant differences between mean (CIT, 18.3 ± 3.7 L·min-1; PLA, 19.0 ± 4.5 L·min-1; p = 0.40) and maximum values (CIT, 28.7 ± 5.7 L·min-1; PLA, 26.6 ± 4.9 L·min-1; p = 0.22) in both trial arms. Mean V̇O2 was 1.77 ± 0.28 and 1.84 ± 0.25 L·min-1 (p = 0.06) for CIT and PLA, respectively. Similarly, mean maximum systolic (165 ± 17 vs. 171 ± 18 mmHg, p = 0.23) and diastolic (81 ± 6 vs. 83 ± 6 mmHg, p = 0.19) blood pressure levels were not significantly different between CIT and PLA trial arms.Discussion: Higher continuous doses of L-citrulline over 10 days do not increase TTE in healthy, moderately active individuals when compared with a placebo. Therefore, it is reasonable to assume that L-citrulline does not offer an ergogenic benefit for endurance performance. However, future research may focus on female populations or exercise protocols that involve longer distances to simulate competition.
DOI 10.3389/fspor.2025.1627743
PMID 40980088
原文・出典を見る →